There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT06422520
Recruiting
This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid tumors. Study details include: * The study will be conducted in 2 phases: Phase 1a (Monotherapy Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion). * The visit frequency will be approximately every 21 days during study treatment. Maximum treatment duratio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Register for Updates
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
NCT06561347
Recruiting
The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264
Recruiting
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Atea Study Site, Boston, Massachusetts
Conditions: HEPATITIS C VIRUS CHRONIC INFECTION
Register for Updates
Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
NCT06777901
Recruiting
The goal of this clinical trial is to learn if the Auryon Atherectomy System with balloon angioplasty safe and effective in treating lower limb blockages. The main question it aims to answer is: Is treatment with Auryon Atherectomy System more effective than angioplasty alone in preventing death, amputation, revascularization and improving patency? Researchers will compare the Auryon Atherectomy System with balloon angioplasty to balloon angioplasty alone.
Gender:
ALL
Ages:
All
Trial Updated:
07/23/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Peripheral Arterial Diseases
Register for Updates
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246
Recruiting
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Harvard University, Boston, Massachusetts
Conditions: Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract, Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
Register for Updates
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they exp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Register for Updates
The Molecular Basis of Inherited Reproductive Disorders
NCT05971836
Recruiting
The goal of this study is to learn more about the genes that control puberty and reproduction in humans.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypogonadotropic Hypogonadism, Reproductive Disorder, Kallmann Syndrome, Delayed Puberty
Register for Updates
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Acute Myeloid Leukemias
Register for Updates
Dampening the Reproductive Axis With Continuous Kisspeptin
NCT05971849
Recruiting
The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Reproductive Disorder, PCOS, Polycystic Ovary Syndrome
Register for Updates
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041
Recruiting
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Schizophrenia
Register for Updates
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983
Recruiting
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital - Boston, Boston, Massachusetts
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates